Pharmacological evidence for glutamatergic pathway involvement in the antidepressant-like effects of 2-phenyl-3-(phenylselanyl)benzofuran in male Swiss mice
Depression is a multifactorial and heterogeneous disease with several neurobiological mechanisms underlying its pathophysiology, including dysfunctional glutamatergic neurotransmission, which makes the exploration of the glutamate pathway an interesting strategy for developing novel rapid-acting ant...
Gespeichert in:
Veröffentlicht in: | Naunyn-Schmiedeberg's archives of pharmacology 2023-11, Vol.396 (11), p.3033-3044 |
---|---|
Hauptverfasser: | , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Depression is a multifactorial and heterogeneous disease with several neurobiological mechanisms underlying its pathophysiology, including dysfunctional glutamatergic neurotransmission, which makes the exploration of the glutamate pathway an interesting strategy for developing novel rapid-acting antidepressant treatments. In the present study, we aimed to evaluate the possible glutamatergic pathway relation in the antidepressant-like action of 2-phenyl-3-(phenylselanyl)benzofuran (SeBZF
1
) in Swiss mice employing the tail suspension test (TST). Male Swiss mice received drugs targeting glutamate receptors before acute SeBZF
1
administration at effective (50 mg/kg) or subeffective (1 mg/kg) doses by intragastric route (
ig
). TST and the open-field test (OFT) were employed in all behavioral experiments. The pretreatment of mice with N-methyl-D-aspartate (NMDA) (0.1 pmol/site, intracerebroventricular,
icv
, a selective agonist of the NMDA receptors), D-serine (30 µg/site,
icv
, a co-agonist at the NMDA receptor), arcaine (1 mg/kg, intraperitoneal,
ip
, an antagonist of the polyamine-binding site at the NMDA receptor), and 6,7-dinitroquinoxaline-2,3-dione (DNQX) (2,5 µg/site,
icv
, an antagonist of the AMPA/kainate type of glutamate receptors) inhibited the antidepressant-like effects of SeBZF
1
(50 mg/kg,
ig
) in the TST. Coadministration of a subeffective dose of SeBZF
1
with low doses of MK-801 (0.001 mg/kg,
ip
, a non-competitive NMDA receptor antagonist) or ketamine (0.1 mg/kg,
ip
, a non-selective antagonist of the NMDA receptors) produced significant antidepressant-like effects (synergistic action). These findings suggest the involvement of the glutamatergic system, probably through modulation of ionotropic glutamate receptors, in the antidepressant-like action of SeBZF
1
in mice and contribute to a better understanding of the mechanisms underlying its pharmacological effects.
Graphical Abstract |
---|---|
ISSN: | 0028-1298 1432-1912 |
DOI: | 10.1007/s00210-023-02508-3 |